Recent News and Upcoming Events

First Light Diagnostics Receives Additional Funding from the Biomedical Advanced Research and Development Authority (BARDA)

For development of the breakthrough MultiPath™  platform and culture-free, anti-microbial susceptibility tests Chelmsford, MA, December 18, 2019 – First Light Diagnostics, Inc., a developer of breakthrough automated products for rapid, diagnosis and treatment of life-threatening, antibiotic-resistant infections, today announced the authorization of $4.3 million in additional funding from BARDA in support of First Light’s development…

Read More

First Light Diagnostics to Present at New England Venture Summit

CHELMSFORD, Mass., December 3, 2019 – First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced David Macdonald, President and CEO of First Light Diagnostics, will be among the presenters at the 2019 New England Venture Summit. The New England Venture Summit is an event that allows…

Read More

Dr. Melvin Weinstein Becomes a Member of First Light Diagnostics Clinical Advisory Board

Chelmsford, MA (November 13, 2019) – First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced the addition of Melvin P. Weinstein, M.D., to the company’s world-class, international Clinical Advisory Board. “Dr. Weinstein is a recognized expert in infectious disease and antimicrobial susceptibility testing…

Read More

First Light Joins Global Initiative to Combat Antibiotic Resistance

Commits to deliver platform to enable targeted treatment at the onset of infection First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced their participation in the U.S. Centers for Disease Control and Prevention (CDC) Antimicrobial Resistance (AMR) Challenge. First Light’s MultiPath™ platform will…

Read More

David Macdonald to Present at BIO Investor Forum

Two-day event highlights investment trends and opportunities in Life Sciences Chelmsford, MA (October 16, 2019) – First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced that First Light’s President & CEO, David Macdonald will be among the presenters at the 2019 BIO Investor…

Read More

What Sets Us Apart?

Our MultiPath benchtop analyzer is advancing the field of rapid diagnostics in several key areas:

Culture Free Results

Culture Free Results

The MultiPath technology outperforms current culture-based methods by providing pathogen identification results in 30 minutes and antimicrobial susceptibility test results in 4 hours…without a sample culture step.
Hours vs. Days

Hours vs. Days

Culture-free test capabilities make MultiPath the ONLY platform capable of delivering diagnostic results in hours as compared to multiple days required for current, culture-based tests.
Therapy at the Onset of Infection

Therapy at the Onset of Infection

Rapid Diagnostic ID/AST results provide timely, actionable data for clinicians to make the best therapy decisions for their patients at the onset of infection.

Meet the Team

Management Team
Board of Directors
Clinical Advisory
Other Advisors
light-purple-logo

How First Light Diagnostics and their MultiPathTM Platform Can Help Patients Receive the Right Therapy at the Onset of Infection

Medical Practitioners Discuss the Causes and Impacts of Antibiotic Resistance and the Effect Rapid Results can Have to Address the Problem

Contact First Light Diagnostics

If you have been watching the continued growth and development of this exciting company and would like to to speak in person with David Macdonald, CEO, and Don Straus, CSO, please fill out the form below and we will work with you to coordinate a one on one meeting.



Role in your Organization*







Recent Publications/Posters

(Peer Reviewed Article) A Rapid, Accurate, Single Molecule Counting Method Detects Clostridium difficile Toxin B in Stool Samples
A New Method for Rapid Phenotypic AST Directly from Patient Samples

Recent Industry articles on the Antibiotic Resistance Problem

Menu